JP2007537704A - ヒト化免疫グロブリン遺伝子座 - Google Patents
ヒト化免疫グロブリン遺伝子座 Download PDFInfo
- Publication number
- JP2007537704A JP2007537704A JP2006520411A JP2006520411A JP2007537704A JP 2007537704 A JP2007537704 A JP 2007537704A JP 2006520411 A JP2006520411 A JP 2006520411A JP 2006520411 A JP2006520411 A JP 2006520411A JP 2007537704 A JP2007537704 A JP 2007537704A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- human
- sequence
- nucleic acid
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 116
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 116
- 241001465754 Metazoa Species 0.000 claims abstract description 143
- 230000009261 transgenic effect Effects 0.000 claims abstract description 123
- 239000013598 vector Substances 0.000 claims abstract description 85
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims abstract description 74
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 54
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 53
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 35
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims abstract description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 173
- 125000006850 spacer group Chemical group 0.000 claims description 154
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 144
- 239000012634 fragment Substances 0.000 claims description 109
- 241000287828 Gallus gallus Species 0.000 claims description 76
- 235000013330 chicken meat Nutrition 0.000 claims description 76
- 239000002773 nucleotide Substances 0.000 claims description 66
- 125000003729 nucleotide group Chemical group 0.000 claims description 66
- 108020004414 DNA Proteins 0.000 claims description 56
- 101150117115 V gene Proteins 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 108091035707 Consensus sequence Proteins 0.000 claims description 22
- 241000288906 Primates Species 0.000 claims description 22
- 101150008942 J gene Proteins 0.000 claims description 21
- 230000008707 rearrangement Effects 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 229940072221 immunoglobulins Drugs 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 12
- 241001494479 Pecora Species 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 241000283707 Capra Species 0.000 claims description 8
- 241000282887 Suidae Species 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 101150097493 D gene Proteins 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 7
- 241000283984 Rodentia Species 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000016784 immunoglobulin production Effects 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract description 10
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract description 6
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 111
- 210000004027 cell Anatomy 0.000 description 52
- 238000010367 cloning Methods 0.000 description 37
- 108091008146 restriction endonucleases Proteins 0.000 description 32
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 108091008109 Pseudogenes Proteins 0.000 description 22
- 102000057361 Pseudogenes Human genes 0.000 description 22
- 229930182566 Gentamicin Natural products 0.000 description 21
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 21
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 21
- 229960002518 gentamicin Drugs 0.000 description 21
- 238000012163 sequencing technique Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 238000010276 construction Methods 0.000 description 18
- 230000006801 homologous recombination Effects 0.000 description 18
- 238000002744 homologous recombination Methods 0.000 description 18
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 17
- 230000006798 recombination Effects 0.000 description 16
- 238000005215 recombination Methods 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 108091092195 Intron Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000001976 enzyme digestion Methods 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 241000271566 Aves Species 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 9
- 241000272517 Anseriformes Species 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 210000004602 germ cell Anatomy 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 229930193140 Neomycin Natural products 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 210000000287 oocyte Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 108020005065 3' Flanking Region Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 108020005029 5' Flanking Region Proteins 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 108010051219 Cre recombinase Proteins 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710116435 Outer membrane protein Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000005220 cytoplasmic tail Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 description 2
- 101150111062 C gene Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010046276 FLP recombinase Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 108010068047 endodeoxyribonuclease AscI Proteins 0.000 description 2
- -1 ethanol Chemical compound 0.000 description 2
- 102000036072 fibronectin binding proteins Human genes 0.000 description 2
- 108091010988 fibronectin binding proteins Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000585705 Alicia <angiosperm> Species 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241001214789 Basilea Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 C[C@](*C1)[C@]1(C(C)C(C1)N)[*+]1C1CC1 Chemical compound C[C@](*C1)[C@]1(C(C)C(C1)N)[*+]1C1CC1 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 101100316841 Escherichia phage lambda bet gene Proteins 0.000 description 1
- 101100226347 Escherichia phage lambda exo gene Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010072863 GACGTC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 108010042546 GCGGCCGC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 101150083678 IL2 gene Proteins 0.000 description 1
- 108700029228 Immunoglobulin Heavy Chain Genes Proteins 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010077674 Tetraspanin 25 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 102000021124 collagen binding proteins Human genes 0.000 description 1
- 108091011142 collagen binding proteins Proteins 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 108010034027 endodeoxyribonuclease FseI Proteins 0.000 description 1
- 108010035806 endodeoxyribonuclease PacI Proteins 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48773303P | 2003-07-15 | 2003-07-15 | |
| PCT/US2004/023226 WO2005007696A2 (en) | 2003-07-15 | 2004-07-15 | Humanized immunoglobulin loci |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011131898A Division JP6017763B2 (ja) | 2003-07-15 | 2011-06-14 | ヒト化免疫グロブリン遺伝子座 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007537704A true JP2007537704A (ja) | 2007-12-27 |
Family
ID=34079388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520411A Withdrawn JP2007537704A (ja) | 2003-07-15 | 2004-07-15 | ヒト化免疫グロブリン遺伝子座 |
| JP2011131898A Expired - Lifetime JP6017763B2 (ja) | 2003-07-15 | 2011-06-14 | ヒト化免疫グロブリン遺伝子座 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011131898A Expired - Lifetime JP6017763B2 (ja) | 2003-07-15 | 2011-06-14 | ヒト化免疫グロブリン遺伝子座 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7585668B2 (enExample) |
| EP (1) | EP1644417B1 (enExample) |
| JP (2) | JP2007537704A (enExample) |
| CN (2) | CN103205436B (enExample) |
| AU (1) | AU2004257292A1 (enExample) |
| CA (1) | CA2532117C (enExample) |
| ES (1) | ES2473596T3 (enExample) |
| IL (1) | IL172885A0 (enExample) |
| MX (1) | MXPA06000562A (enExample) |
| WO (1) | WO2005007696A2 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516071A (ja) * | 2008-04-10 | 2011-05-26 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | シス作用性多様化活性化因子および核酸の選択的多様化のための方法 |
| JP2014529998A (ja) * | 2011-09-19 | 2014-11-17 | カイマブ・リミテッド | ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖 |
| JP2020150951A (ja) * | 2009-07-08 | 2020-09-24 | カイマブ・リミテッド | 動物モデルおよび治療用分子 |
| JP2021516954A (ja) * | 2018-03-21 | 2021-07-15 | クリスタル バイオサイエンス インコーポレイテッドＣｒｙｓｔａｌ Ｂｉｏｓｃｉｅｎｃｅ Ｉｎｃ． | ヒト型抗体を産生するトランスジェニックニワトリ |
| JP2023508290A (ja) * | 2019-12-18 | 2023-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | 共通のリーダー配列を有するｂｃｒトランスジェニックマウス |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA06000562A (es) * | 2003-07-15 | 2006-03-30 | Therapeutic Human Polyclonals | Loci de inmunoglobulina humanizada. |
| WO2007140457A2 (en) * | 2006-05-31 | 2007-12-06 | Genzyme Corporation | Methods of using anti-thymocyte globulin and related agents |
| WO2008027986A2 (en) * | 2006-09-01 | 2008-03-06 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| US20090053210A1 (en) | 2006-09-01 | 2009-02-26 | Roland Buelow | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| EP2602323B1 (en) * | 2007-06-01 | 2018-02-28 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
| US9693539B2 (en) * | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| KR101563017B1 (ko) * | 2007-08-14 | 2015-10-23 | 오리겐 테라퓨틱스 인코포레이티드 | 불활성화된 내인성 유전자좌를 갖는 트랜스제닉 닭 |
| CN112690250B (zh) * | 2008-12-18 | 2024-03-08 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
| EP2464220A4 (en) * | 2009-08-13 | 2014-05-07 | Crystal Bioscience Inc | Transgenic animal for the production of antibodies with minimal complementarity-determining regions |
| US8865462B2 (en) * | 2010-01-20 | 2014-10-21 | Crystal Bioscience Inc. | Sustained culture of avian gonocytes |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| KR102004106B1 (ko) | 2010-03-31 | 2019-07-25 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
| SI2480676T1 (sl) | 2010-06-22 | 2016-10-28 | Regeneron Pharmaceuticals, Inc. | Hibridna mišja lahka veriga |
| RU2612903C2 (ru) | 2010-08-02 | 2017-03-13 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
| CN102250239B (zh) * | 2011-06-13 | 2013-04-17 | 中国农业科学院哈尔滨兽医研究所 | 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用 |
| HUE068728T2 (hu) | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| PL3216871T3 (pl) | 2011-10-17 | 2022-03-21 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
| MX378871B (es) | 2011-12-20 | 2025-03-10 | Regeneron Pharma | Ratones con cadena ligera humanizada. |
| EP2794662A1 (en) | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| PL2809150T3 (pl) * | 2012-02-01 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL |
| KR102213535B1 (ko) | 2012-03-16 | 2021-02-08 | 리제너론 파마슈티칼스 인코포레이티드 | pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물 |
| EP3348140B1 (en) | 2012-03-16 | 2020-12-30 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| EP2858487B1 (en) | 2012-06-12 | 2019-10-23 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| WO2014022853A1 (en) * | 2012-08-03 | 2014-02-06 | Sanford Applied Biosciences, L.L.C. | Complex chromosome engineering for production of human antibodies in transgenic animals |
| RS57582B1 (sr) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| RU2015143108A (ru) * | 2013-03-13 | 2017-04-20 | Регенерон Фарматютикалз, Инк. | Мышь с общей легкой цепью |
| PT3501272T (pt) * | 2013-03-13 | 2023-03-29 | Regeneron Pharma | Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina |
| WO2015103999A1 (en) * | 2014-01-10 | 2015-07-16 | Hung Alfur Fu-Hsin | Transgenic animals capable of producing humanized ige at much higher levels than mouse ige |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| RU2016141307A (ru) | 2014-03-21 | 2018-04-24 | Регенерон Фармасьютикалз, Инк. | Отличные от человека животные, которые вырабатывают однодоменные связывающие белки |
| DK3138903T3 (da) * | 2014-05-02 | 2022-04-19 | Chiome Bioscience Inc | Celler til produktion af humant antistof |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| MA53935A (fr) * | 2016-11-04 | 2021-12-22 | Regeneron Pharma | Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée |
| CN110149809B (zh) | 2016-12-05 | 2023-04-14 | 皇家飞利浦有限公司 | 无线功率传输系统中的异物检测 |
| SG10202109874VA (en) | 2017-01-19 | 2021-10-28 | Open Monoclonal Tech Inc | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
| JP2021508471A (ja) | 2017-12-29 | 2021-03-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法 |
| JP7354306B2 (ja) | 2019-06-27 | 2023-10-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子 |
| AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| CN110540996B (zh) * | 2019-08-29 | 2022-01-28 | 华中农业大学 | 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用 |
| CR20240246A (es) | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| CN114854901B (zh) * | 2022-06-22 | 2025-11-07 | 华南农业大学 | 与苦瓜全雌性状共分离的分子标记、引物及其应用 |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012437A2 (en) * | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production of humanized antibodies in transgenic animals |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411881A (en) | 1990-07-10 | 1995-05-02 | Nkk Corporation | Chicken-specific immunoglobulin G-producing hybridoma |
| KR100272077B1 (ko) * | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| EP0583980A1 (en) | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Method for generating monoclonal antibodies from rabbits |
| AU7326796A (en) | 1995-10-30 | 1997-05-22 | Spectral Diagnostics Inc. | Stable chicken b-cell line and method of use thereof |
| JP5694623B2 (ja) | 1999-02-05 | 2015-04-01 | セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド | 遺伝子操作した動物から得られるヒトポリクローナル抗体 |
| CA2375441A1 (en) | 1999-06-04 | 2000-12-14 | Tranxenogen, Inc. | Methods for manipulating the avian genome |
| AU7491800A (en) | 1999-09-15 | 2001-04-17 | Therapeutic Human Polyclonals, Inc. | Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds |
| EP1539785B1 (en) | 2002-06-26 | 2009-05-06 | Transgenrx, Inc. | Gene regulation in transgenic animals using a transposon-based vector |
| MXPA06000562A (es) * | 2003-07-15 | 2006-03-30 | Therapeutic Human Polyclonals | Loci de inmunoglobulina humanizada. |
| EP1782360A4 (en) | 2004-08-27 | 2009-03-18 | Medic4All Ag | METHOD AND SYSTEM FOR THE USE OF A MOBILE DEVICE AS A PORTABLE PERSONAL TERMINAL FOR MEDICAL INFORMATION |
| US20110077965A1 (en) | 2009-09-25 | 2011-03-31 | Cerner Innovation, Inc. | Processing event information of various sources |
| US20120306653A1 (en) | 2011-06-02 | 2012-12-06 | Nokia Siemens Networks Oy | Medical sensor |
| US20130021154A1 (en) | 2011-07-21 | 2013-01-24 | Solomon Clifford T | Medical parameters notification system |
-
2004
- 2004-07-15 MX MXPA06000562A patent/MXPA06000562A/es unknown
- 2004-07-15 CA CA2532117A patent/CA2532117C/en not_active Expired - Lifetime
- 2004-07-15 JP JP2006520411A patent/JP2007537704A/ja not_active Withdrawn
- 2004-07-15 ES ES04778633.0T patent/ES2473596T3/es not_active Expired - Lifetime
- 2004-07-15 CN CN201210390234.2A patent/CN103205436B/zh not_active Expired - Lifetime
- 2004-07-15 CN CNA2004800261928A patent/CN1852925A/zh active Pending
- 2004-07-15 US US10/893,483 patent/US7585668B2/en active Active
- 2004-07-15 AU AU2004257292A patent/AU2004257292A1/en not_active Abandoned
- 2004-07-15 WO PCT/US2004/023226 patent/WO2005007696A2/en not_active Ceased
- 2004-07-15 EP EP04778633.0A patent/EP1644417B1/en not_active Expired - Lifetime
-
2005
- 2005-12-29 IL IL172885A patent/IL172885A0/en unknown
-
2009
- 2009-07-29 US US12/511,188 patent/US8410333B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011131898A patent/JP6017763B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-27 US US13/779,585 patent/US8652842B2/en not_active Ceased
-
2016
- 2016-02-09 US US15/019,852 patent/USRE47131E1/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012437A2 (en) * | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production of humanized antibodies in transgenic animals |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516071A (ja) * | 2008-04-10 | 2011-05-26 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | シス作用性多様化活性化因子および核酸の選択的多様化のための方法 |
| JP2020150951A (ja) * | 2009-07-08 | 2020-09-24 | カイマブ・リミテッド | 動物モデルおよび治療用分子 |
| JP7141427B2 (ja) | 2009-07-08 | 2022-09-22 | カイマブ・リミテッド | 動物モデルおよび治療用分子 |
| JP2014529998A (ja) * | 2011-09-19 | 2014-11-17 | カイマブ・リミテッド | ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖 |
| JP2021516954A (ja) * | 2018-03-21 | 2021-07-15 | クリスタル バイオサイエンス インコーポレイテッドＣｒｙｓｔａｌ Ｂｉｏｓｃｉｅｎｃｅ Ｉｎｃ． | ヒト型抗体を産生するトランスジェニックニワトリ |
| JP7779655B2 (ja) | 2018-03-21 | 2025-12-03 | クリスタル バイオサイエンス インコーポレイテッド | ヒト型抗体を産生するトランスジェニックニワトリ |
| JP2023508290A (ja) * | 2019-12-18 | 2023-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | 共通のリーダー配列を有するｂｃｒトランスジェニックマウス |
| JP7716406B2 (ja) | 2019-12-18 | 2025-07-31 | ブリストル－マイヤーズ スクイブ カンパニー | 共通のリーダー配列を有するｂｃｒトランスジェニックマウス |
Also Published As
| Publication number | Publication date |
|---|---|
| US8652842B2 (en) | 2014-02-18 |
| CA2532117A1 (en) | 2005-01-27 |
| IL172885A0 (en) | 2006-06-11 |
| EP1644417A2 (en) | 2006-04-12 |
| US20100205682A1 (en) | 2010-08-12 |
| CA2532117C (en) | 2012-07-10 |
| EP1644417B1 (en) | 2014-04-30 |
| CN103205436B (zh) | 2016-05-25 |
| US20060026696A1 (en) | 2006-02-02 |
| MXPA06000562A (es) | 2006-03-30 |
| US8410333B2 (en) | 2013-04-02 |
| JP2011182801A (ja) | 2011-09-22 |
| CN1852925A (zh) | 2006-10-25 |
| US20130189774A1 (en) | 2013-07-25 |
| USRE47131E1 (en) | 2018-11-20 |
| JP6017763B2 (ja) | 2016-11-02 |
| US7585668B2 (en) | 2009-09-08 |
| WO2005007696A2 (en) | 2005-01-27 |
| CN103205436A (zh) | 2013-07-17 |
| AU2004257292A1 (en) | 2005-01-27 |
| ES2473596T3 (es) | 2014-07-07 |
| WO2005007696A3 (en) | 2005-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6017763B2 (ja) | ヒト化免疫グロブリン遺伝子座 | |
| JP6824807B2 (ja) | 抗体産生非ヒト哺乳動物 | |
| US7129084B2 (en) | Production of humanized antibodies in transgenic animals | |
| EP2931030B1 (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same | |
| US20050153392A1 (en) | Transgenesis with humanized immunoglobulin loci | |
| US8354568B2 (en) | Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin | |
| AU2001284703A1 (en) | Production of humanized antibodies in transgenic animals | |
| KR20110089846A (ko) | 키메라 항체의 제조를 위한 인간 이외의 포유동물 | |
| EP1690934A2 (en) | Generation of xenogeneic antibodies | |
| CN110662421B (zh) | 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体 | |
| HK40029423A (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same | |
| HK40029423B (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same | |
| ZA200301723B (en) | Production of humanized antibodies in transgenic animals. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081212 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100629 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100928 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101115 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110614 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110808 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110811 |